RA
CNTA

Royce & Associates’s Centessa Pharmaceuticals CNTA Stock Holding History

Royce & Associates’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11M Sell
278,064
-84,809
-23% -$2.17M 0.11% 297
2025
Q4 		$9.08M Buy
362,873
+115,486
+47% +$2.93M 0.09% 339
2025
Q3 		$6M Buy
+247,387
New +$4.4M 0.06% 434

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Royce & Associates's CNTA Position: Q1 2026 in Review

Royce & Associates reduced its Centessa Pharmaceuticals (CNTA) stake by 23% in Q1 2026, selling an estimated $2.17M and leaving 278,064 shares worth $11M. The position accounts for 0.11% of the portfolio, ranked #297.

Royce & Associates first reported a position in CNTA in Q3 2025 and has held it in 3 quarters since. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Royce & Associates held 278,064 shares of Centessa Pharmaceuticals worth $11M as of Q1 2026.
  • Royce & Associates sold 84,809 Centessa Pharmaceuticals shares in Q1 2026, an estimated $2.17M.
  • Centessa Pharmaceuticals made up 0.11% of Royce & Associates's portfolio in Q1 2026, its #297 holding.
  • Royce & Associates first reported a position in Centessa Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Royce & Associates's 13F filing for Q1 2026, filed 12 May 2026.